News & Events

  • 2nd Annual RNA as a Drug Target Conference

    When: Sep. 16th, 2020 to Sep. 18th, 2020

    Anima Biotech has been invited to present and participate on an expert panel during the Cambridge Healthtech Institute’s 2nd Annual RNA as a Drug Target Conference, between Sep. 16-17, 2020. Yochi Slonim, Co-founder and CEO of Anima Biotech, will be giving a presentation during the RNA as a Drug Target session, titled, “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators, on Thursday, Sep. 17 at 10:15 a.m. ET. As part of the same session, Dr. Iris Alroy, VP of R&D, will participate on an expert wrap-up panel discussion on Thursday, Sep. 17 at 11:35 a.m. ET.

    In the past year, the idea of targeting RNA directly with either a small molecule-like drug or with oligonucleotides has gone from an interesting idea to a viable business plan. During the 2nd Annual RNA as a Drug Target Conference, part of the Discovery on Target, attendees will discuss not only the identification of specific and potent novel binders of RNA, but also the unique challenges that come with a novel drug target class.

    Download Press Release »

    Visit the conference website »

  • Cambridge Healthtech Institute’s Inaugural RNA as a Small Molecule Target Symposium

    When: Aug. 28th, 2020

    Anima Biotech has been invited to give an overview of its Translation Control Therapeutics platform at the Inaugural RNA as a Small Molecule Target Symposium. Co-founder and CEO, Yochi Slonim and vice president of research and development Dr. Iris Alroy will jointly present a talk titled “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators,” on Friday, Aug. 28 at 3 p.m. ET.

    RNA molecules are crucial for delivering cellular information and genetic regulation, but until recently, the drug discovery world has emphasized protein drug targets. Our lack of knowledge in RNA biology prevented us from exploring possibilities of RNA drug targets, but with recent advances in technologies, such as sequencing, new therapeutic strategies are being explored. The Inaugural RNA as a Small Molecule Target symposium, part of Drug Discovery Chemistry, will discuss methods and tools to identify specific, potent, novel, small molecule binders of RNA.

    Download Press Release »

    Visit the conference website »

  • ChinaBio Partnering Forum

    When: Aug. 25th, 2020 to Aug. 27th, 2020

    Anima Biotech’s co-founder and CEO, Yochi Slonim, has been invited to present about its business, technology and partnering strategies during the ChinaBio Partnering Forum 2020.

    The ChinaBio Partnering Forum is the premier life science partnering event in China. The event attracts biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.

    Download Press Release »

    Visit the conference website »

  • 4th Annual IPF Summit 2020

    When: Aug. 24th, 2020 to Aug. 26th, 2020

    Anima Biotech’s vice president of research and development, Iris Alroy, Ph.D., has been invited to give an overview of the company’s lung-specific modulators of collagen translation and recent in vivo data at the 4th Annual IPF Summit. Dr. Alroy’s presentation titled “Found in Translation: Targeting Collagen I Protein Synthesis as a Novel Therapeutic Approach for IPF,” will take place on Tuesday, Aug. 25 at 2 p.m. ET.

    This year’s IPF Summit will be entirely digital as the only and most comprehensive summit committed to addressing the translational and clinical challenges limiting the idiopathic pulmonary fibrosis industry from transforming patient’s lives with more effective and meaningful drug development. The summit attracts cross-industry experts alongside pioneering academics from IPF drug sponsors to those strategically assessing anti-fibrotic drug development for archetypal fibrotic diseases. The conference highlights the latest interrogation of pathophysiology, genetics, and drug mechanisms to constructively outlining the lumping versus splitting debate, and a world with COVID-19 to advance the IPF drug development frontier.

    Download Press Release »

    Visit the conference website »

  • BIO Digital Week

    When: Jun. 8th, 2020 to Jun. 12th, 2020

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation and provide an update on its drug discovery pipeline during the 2020 BIO Digital Week.

    The conference, a virtual format for the annual BIO International Convention, is bringing together more than 6,500 attendees from 64 countries around the world for an exciting week of BIO One-on-One partnering, critical education and thought leaders discussing the most pressing industry topics.

    Visit the conference website »

  • 13th Annual European Life Sciences CEO Forum

    When: Feb. 19th, 2020 to Feb. 20th, 2020
    Where: Zurich, Switzerland

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 13th Annual European Life Sciences CEO Forum.

    The conference serves as a global biopharma industry forum that addresses the main challenges for 2020 investment, partnering and alliance management. Key players contribute their insights via panels, which cover the macro picture and innovation in different therapeutic sectors. The forum also features keynote speeches by KOLs and approximately 60 corporate presentations from established public and private emerging biotech companies.

    Download Press Release »

    Visit the conference website »

  • 2020 BIO CEO & Investor Conference

    When: Feb. 10th, 2020 to Feb. 11th, 2020
    Where: New York, USA

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 2020 BIO CEO & Investor Conference.

    Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private companies. The conference prides itself on showcasing the best of biotech with two days of productive partnering meetings with institutional and early-stage investors, industry analysts and senior biotechnology executives.

    Download Press Release »

    Visit the conference website »

  • 6th Annual LSX World Congress

    When: Feb. 4th, 2020 to Feb. 5th, 2020
    Where: London, UK

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 6thAnnual LSX World Congress. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will also participate with other experts as part of the “Platforms and Partnerships” panel.

    For five years, the LSX World Congress has been bringing together the executives that matter to the future of healthcare and life science business strategy, investment, partnering, deal-making, and commercialization. The LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly listed life science giants and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.

     

    Download Press Release »

    Visit the conference website »

  • Biotech Showcase 2020

    When: Jan. 13th, 2020 to Jan. 15th, 2020
    Where: San Francisco, USA

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the Biotech ShowcaseTM 2020.

    Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this important week which sets the tone for the coming year. Now in its twelfth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings.

    Download Press Release »

    Visit the conference website »

  • 2nd RNA- Targeted Drug Discovery Summit 2019

    When: Dec. 2nd, 2019 to Dec. 4th, 2019
    Where: Boston, USA

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 2nd RNA- Targeted Drug Discovery Summit 2019. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will also participate with other experts as part of the “Targeting RNA with Small Molecules to Capture the Therapeutic Opportunities” panel.

    With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting RNA, the 2nd RNA- Targeted Drug Discovery Summit is the only industry and translational focused conference dedicated to advancing pioneering RNA targeted small molecule therapeutics. For the 2nd year, at this event KOLs and RNA pioneers join to gain a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic, delve into the exciting field of epitranscriptomics and stimulate discussion on how to successfully target RNA via RNA- modifying enzymes and interfering with RNA-protein interactions.

    Download Press Release »

    Visit the conference website »

Pages